Sept 21 (Reuters) – ADARx Pharmaceuticals is seeking a valuation of up to $1.74 billion in its U.S. initial public offering, the company said on Monday, as investor appetite for biotech listings
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Utah Royals FC did more than win a playoff game Friday night. Kiana Palacios scored…
Christian Bliss came off the bench to bury four 3-pointers, Nick Townsend scored a game-high…
Amari Allen recorded the fifth triple-double in Alabama history with 16 points, 13 rebounds and…
BENGALURU, Nov 7 (Reuters) - Delhi was the world's most polluted major city on Saturday…
The milestone marks a significant chapter in the company’s growth journey, transitioning from the BSE…
Nov 7 (Stats Perform) - Results from the NCAAB games on Friday (home team in…